CD30+ Primary Cutaneous Anaplastic Large Cell Lymphoma

  • Amrita Goyal
  • Joi B. Carter
  • Jeffrey A. Barnes
  • Nicole R. LeBoeuf
  • Lyn McDivitt DuncanEmail author


Primary cutaneous anaplastic large cell lymphoma (pcALCL), a member of the spectrum of CD30+ lymphoproliferative diseases, has an excellent prognosis. This indolent lymphoma is the second most common of all cutaneous T-cell lymphomas. It typically presents with solitary cutaneous and subcutaneous erythematous-to-violaceous papules and nodules. Although relapse after treatment is very common, patients are typically asymptomatic, and the vast majority do not experience extracutaneous spread.


Primary cutaneous anaplastic large cell lymphoma CD30 CD30+ lymphoproliferative disease CD4+ Lymphomatoid papulosis Systemic anaplastic large cell lymphoma Mycosis fungoides CD30+ large cell transformation Adult T-cell leukemia/lymphoma (ALCL) 


  1. 1.
    Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol. 2003;49:1049–58.PubMedCrossRefGoogle Scholar
  2. 2.
    Ralfkiaer E, Willemze R, Paulli M, Kadin ME, et al. Primary cutaneous CD30-positive T-cell lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumors of hematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008. p. 300–1.Google Scholar
  3. 3.
    Bekkenk MW, Geelen AMJ, Vader PCVV, Heule F, Geerts M, van Vloten WA, et al. Primary and secondary cutaneous CD30 lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95:3653–61.PubMedGoogle Scholar
  4. 4.
    Beljaards RC, Kaudewitz P, Berti E, Gianotti R, Neumann C, Rosso R, et al. Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis. A European Multicenter Study of 47 patients. Cancer. 1993;71:2097–104.PubMedCrossRefGoogle Scholar
  5. 5.
    Berge RL, Oudejans JJ, Ossenkoppele GJ, Pulford K, Willemze R, Falini B, et al. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol. 2000;53:445–50.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111:5496–504.PubMedCrossRefGoogle Scholar
  7. 7.
    Stein H, Foss H, Dürkop H, Marafioti T, Delsol G, Pulford K, et al. Review article. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2013;96(12):3681–95.Google Scholar
  8. 8.
    Drews R, Samel A, Kadin ME. Lymphomatoid papulosis and anaplastic large cell lymphomas of the skin. Semin Cutan Med Surg. 2000;19:109–17.PubMedCrossRefGoogle Scholar
  9. 9.
    Shehan JM, Kalaaji AN, Markovic SN, Ahmed I. Management of multifocal primary cutaneous CD30 anaplastic large cell lymphoma. J Am Acad Dermatol. 2004;51:103–10.PubMedCrossRefGoogle Scholar
  10. 10.
    Yu JB, McNiff JM, Lund MW, Wilson LD. Treatment of primary cutaneous CD30+ anaplastic large-cell lymphoma with radiation therapy. Int J Radiat Oncol Biol Phys. 2008;70:1542–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Blume JE, Stoll HL, Cheney RT. Treatment of primary cutaneous CD30+ anaplastic large cell lymphoma with intralesional methotrexate. J Am Acad Dermatol. 2006;54:S229–30.PubMedCrossRefGoogle Scholar
  12. 12.
    Oliveira A, Fernandes I, Alves R, Lima M, Selores M. Primary cutaneous CD30 positive anaplastic large cell lymphoma – report of a case treated with bexarotene. Leuk Res. 2011;35:e190–2.PubMedCrossRefGoogle Scholar
  13. 13.
    Kutok JL. Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. J Clin Oncol. 2002;20:3691–702.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Amrita Goyal
    • 1
  • Joi B. Carter
    • 2
  • Jeffrey A. Barnes
    • 3
  • Nicole R. LeBoeuf
    • 4
  • Lyn McDivitt Duncan
    • 5
    Email author
  1. 1.Harvard-MIT Division of Health Sciences and TechnologyHarvard Medical SchoolBostonUSA
  2. 2.Department of DermatologyMassachusetts General Hospital, Harvard Medical SchoolBostonUSA
  3. 3.Comprehensive Cutaneous Lymphoma Program, Department of MedicineMassachusetts General Hospital Cancer CenterBostonUSA
  4. 4.Department of DermatologyBrigham and Women’s Hospital, Harvard Medical SchoolBostonUSA
  5. 5.Dermatopathology Service, Department of PathologyMassachusetts General Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations